Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Profit After Tax (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Profit After Tax for 13 consecutive years, with -$58.6 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 1.37% to -$58.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$288.3 million through Dec 2025, up 38.12% year-over-year, with the annual reading at -$288.3 million for FY2025, 38.12% up from the prior year.
  • Profit After Tax for Q4 2025 was -$58.6 million at Madrigal Pharmaceuticals, up from -$114.2 million in the prior quarter.
  • The five-year high for Profit After Tax was -$42.3 million in Q2 2025, with the low at -$152.0 million in Q2 2024.
  • Average Profit After Tax over 5 years is -$83.3 million, with a median of -$75.1 million recorded in 2023.
  • The sharpest move saw Profit After Tax plummeted 91.87% in 2024, then skyrocketed 72.18% in 2025.
  • Over 5 years, Profit After Tax stood at -$64.5 million in 2021, then plummeted by 33.08% to -$85.9 million in 2022, then plummeted by 30.6% to -$112.2 million in 2023, then skyrocketed by 47.04% to -$59.4 million in 2024, then rose by 1.37% to -$58.6 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$58.6 million, -$114.2 million, and -$42.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.